159 related articles for article (PubMed ID: 33444473)
21. "
Malvika S; Parikshaa G; Nalini G; Sujata S; Veenu S; Bhavana R; Rashmi B
Int J Surg Pathol; 2023 Aug; 31(5):714-720. PubMed ID: 35975574
[TBL] [Abstract][Full Text] [Related]
22. Manifestation of an undifferentiated uterine sarcoma in a 51 years old patient and its prognosis: A case report.
Pantelić M; Gvozdenovic L; Panjković M; Stojić M; Stajić D; Petrić A; Trajković SP; Trenkić M; Simić D; Živadinović L; Živadinović A
Medicine (Baltimore); 2022 Dec; 101(52):e32552. PubMed ID: 36596037
[TBL] [Abstract][Full Text] [Related]
23. A mediator complex subunit 12 gain-of-function mutation induces partial leiomyoma cell properties in human uterine smooth muscle cells.
Takao T; Ono M; Yoshimasa Y; Masuda H; Maruyama T
F S Sci; 2022 Aug; 3(3):288-298. PubMed ID: 35643626
[TBL] [Abstract][Full Text] [Related]
24. Osteosarcoma arising in a long-standing uterine leiomyoma: a case report and literature review.
Wang RC; Wen MC; Wang J; Ho SC; Jan YJ
Int J Surg Pathol; 2011 Feb; 19(1):99-103. PubMed ID: 19017661
[TBL] [Abstract][Full Text] [Related]
25. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
26. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
27. Two uncommon cases of uterine leiomyosarcomas displaying heterologous osteosarcomatous de-differentiation.
Parikh P; Maheshwari A; Rekhi B
J Cancer Res Ther; 2015; 11(3):654. PubMed ID: 26458644
[TBL] [Abstract][Full Text] [Related]
28. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
29. Metastatic low-grade endometrial stromal sarcoma of uterus presenting as a primary pancreatic tumor: case presentation and literature review.
McCarthy AJ; Clarke BA; McGilvray I; Dickson BC; Khalili K; Chetty R
Diagn Pathol; 2019 Apr; 14(1):30. PubMed ID: 31010432
[TBL] [Abstract][Full Text] [Related]
30. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.
Heinonen HR; Pasanen A; Heikinheimo O; Tanskanen T; Palin K; Tolvanen J; Vahteristo P; Sjöberg J; Pitkänen E; Bützow R; Mäkinen N; Aaltonen LA
Sci Rep; 2017 Apr; 7(1):1015. PubMed ID: 28432313
[TBL] [Abstract][Full Text] [Related]
31. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
32. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
33. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
34. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
35. Frequency of MED12 Mutation in Relation to Tumor and Patient's Clinical Characteristics: a Meta-analysis.
He C; Nelson W; Li H; Xu YD; Dai XJ; Wang YX; Ding YB; Li YP; Li T
Reprod Sci; 2022 Feb; 29(2):357-365. PubMed ID: 33569750
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth.
Bloch J; Holzmann C; Koczan D; Helmke BM; Bullerdiek J
Oncotarget; 2017 May; 8(21):34762-34772. PubMed ID: 28410233
[TBL] [Abstract][Full Text] [Related]
37. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
38. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
39. Deep sequencing reveals the molecular pathology characteristics between primary uterine leiomyoma and pulmonary benign metastasizing leiomyoma.
Jiang J; He M; Hu X; Ni C; Yang L
Clin Transl Oncol; 2018 Aug; 20(8):1080-1086. PubMed ID: 29484624
[TBL] [Abstract][Full Text] [Related]
40. Med12 gain-of-function mutation causes leiomyomas and genomic instability.
Mittal P; Shin YH; Yatsenko SA; Castro CA; Surti U; Rajkovic A
J Clin Invest; 2015 Aug; 125(8):3280-4. PubMed ID: 26193636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
